Tecentriq takes lead in China for extensive-stage small cell lung cancer
Continuing its progress in addressing different cancer types across different geographies, immuno-oncology blockbuster Tecentriq (atezolizumab) has secured Chinese approval in extensive-stage small cell lung cancer (ES-SCLC).
Last year, Roche (ROG: SIX) became the first company to offer an immuno-oncology option for people with this kind of cancer, when it won approval in Europe and in the USA, ahead of rival options from AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK).
Approval in China will help the Swiss cancer giant entrench its lead, with Tecentriq taking in 1.88 billion Swiss francs ($1.9 billion) in 2019, up 143% from the year before. In the fourth quarter revenues were 248 million Swiss francs, up 136% from the like period of 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze